多西紫杉醇联合奥沙利铂治疗晚期非小细胞肺癌的临床观察  

A clinical observation for docetaxel combined oxaliplatin in the treatment of advanced non-small cell lung cancer

作　　者：何安兵 罗仁峰[2] 

机构地区：[1]武汉市五医院肿瘤科,湖北武汉430050 [2]江汉大学医学院,湖北武汉430056

出　　处：《现代肿瘤医学》2010年第1期100-101,共2页Journal of Modern Oncology

摘　　要：目的:观察多西紫杉醇每周给药联合奥沙利铂一线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:选择有病理理诊断的肺癌病人35例,给予多西紫杉醇35mg/(m2.d),d1,8;奥沙利铂130mg/(m.2d),d1;21d为1个周期。每位患者至少接受2个周期化疗。结果:35例患者中CR2例,PR16例,SD11例,PD6例,总有效率(RR)为51.4%(18/35),临床获益率为82.8%(29/35),TTP4.4个月,MST11个月,1年生存率42.8%(15/35)。常见不良反应为脱发、乏力和感觉神经异常,但症状轻,Ⅲ-Ⅳ度粒细胞减少11.4%(4/35),全组无治疗相关性死亡。结论:多西他赛每周给药联合奥沙利铂一线治疗晚期非小细胞肺癌疗效确切,不良反应较轻,耐受性好,是一种安全有效、值得临床推广应用的方法。Objective：To observe the clinical effect and side reaction of the two - drug combination of docetaxel （DOC） weekly and oxaliplatin （OXA） as first line therapy for advanced non -small cell lung cancer （NSCLC）. Methods ：Thirty -five patients of lung cancer with pathological diagnosis were treated with DOC 35mg/（ m^2 · d） on d1 , d8 ; OXA 1-30mg/（ m ^2 · d） on d1. 21 days as one cycle and every patient accepted for 2 cycles at least. Results： The complete remission （ CR）, partial remission （ PR）, stable disease （SD）, and progress of disease （PD） were 2 cases, 16 cases, 11 cases, and 6 cases respectively in 35 patients. The response rate （RR） and clinical benefit response （CR PR SD） were 51.4% （18/35） and 82.8% （29/35） respectively. The time to progression（ TTP）, mean survival time （ MST）, and 1 - year survival were 4.4 months, 11 months, and 42.8% （ 15/35 ） respectively. The main side effect was alopecia, acratia and sensory nerve pathology but the symptom was mild. The granulocytopenia Ⅲ - Ⅳ was 11. 4% （4/35） and there was no treatment -related dealth. Conclution：h is effective that DOC weekly coupled with OXA as first - line therapy for NSCLC.

关 键 词：多西紫彬醇 奥沙利铂 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]